GDRX (Health Care Technology) Stock Valuation & Fair Value Fairly valued
GDRX (Health Care Technology) trades at a blended P/E of 9.8, about 73% below its historical normal valuation, with a forward growth estimate of 7.0% and a PEG of 1.40. Analysts' one-year estimates have been hit 40% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is GDRX overvalued?
At a blended P/E of 9.8 versus its historical normal P/E of 35.8, GDRX trades about 73% below its typical valuation, with a PEG of 1.40 on 7.0% forward growth. tickerseer currently rates it fairly valued.
What is GDRX's fair value and PEG?
GDRX trades at a blended P/E of 9.8 against a historical normal P/E of 35.8, a PEG of 1.40, and a forward growth estimate of 7.0%.
Has tickerseer's rating of GDRX changed?
tickerseer's rating has been fairly valued since 2026-07-31.
Industry: Health Care Technology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.